The challenge of choosing in cardiovascular risk management.

Autor: Hoogeveen RM; Department of Vascular Medicine, Amsterdam University Medical Centres, location AMC, Amsterdam, The Netherlands., Hanssen NMJ; Department of Vascular Medicine, Amsterdam University Medical Centres, location AMC, Amsterdam, The Netherlands., Brouwer JR; Medcon International, Heemstede, The Netherlands., Mosterd A; Department of Cardiology, Meander Medical Centre, Amersfoort, The Netherlands., Tack CJ; Department of Internal Medicine, University Medical Centre Nijmegen, Nijmegen, The Netherlands., Kroon AA; Department of Internal Medicine and Cardiovascular Research Institute Maastricht (CARIM), Maastricht University Medical Centre (MUMC+), Maastricht, The Netherlands., de Borst GJ; Department of Vascular Surgery, University Medical Centre Utrecht, Utrecht, The Netherlands., Ten Berg J; Department of Cardiology, Sint-Antonius Ziekenhuis, Nieuwegein, The Netherlands., van Trier T; Department of Cardiology, Amsterdam University Medical Centres, location AMC, Amsterdam, The Netherlands., van Lennep JR; Department of Internal Medicine, Erasmus MC, University Medical Centre Rotterdam, Rotterdam, The Netherlands., Liem A; Department of Cardiology, Sint Franciscus Gasthuis, Rotterdam, The Netherlands., Serné E; Department of Vascular Medicine, Amsterdam University Medical Centres, location VUmc, Amsterdam, The Netherlands., Visseren FLJ; Department of Vascular Medicine, University Medical Centre Utrecht, Utrecht, The Netherlands., Cornel JH; Department of Cardiology, Radboud University Medical Centre, Nijmegen, The Netherlands.; Department of Cardiology, Northwest Clinics, Alkmaar, The Netherlands., Peters RJG; Department of Cardiology, Amsterdam University Medical Centres, location AMC, Amsterdam, The Netherlands., Jukema JW; Department of Cardiology, Leiden University Medical Centre, Leiden, The Netherlands., Stroes ESG; Department of Vascular Medicine, Amsterdam University Medical Centres, location AMC, Amsterdam, The Netherlands. e.s.stroes@amsterdamumc.nl.
Jazyk: angličtina
Zdroj: Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation [Neth Heart J] 2022 Jan; Vol. 30 (1), pp. 47-57. Date of Electronic Publication: 2021 Jul 14.
DOI: 10.1007/s12471-021-01599-y
Abstrakt: Cardiovascular disease (CVD) is a major cause of morbidity and mortality worldwide. For many years guidelines have listed optimal preventive therapy. More recently, novel therapeutic options have broadened the options for state-of-the-art CV risk management (CVRM). In the majority of patients with CVD, risk lowering can be achieved by utilising standard preventive medication combined with lifestyle modifications. In a minority of patients, add-on therapies should be considered to further reduce the large residual CV risk. However, the choice of which drug combination to prescribe and in which patients has become increasingly complicated, and is dependent on both the absolute CV risk and the reason for the high risk. In this review, we discuss therapeutic decisions in CVRM, focusing on (1) the absolute CV risk of the patient and (2) the pros and cons of novel treatment options.
(© 2021. The Author(s).)
Databáze: MEDLINE
Externí odkaz: